The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | SATISFY: mitapivat in patients with erythrocyte membranopathies
Kevin Kuo, MD, MSc, FRCPC, University Health Network, Toronto, Canada, introduces the SATISFY study (NCT05935202), a prospective, single-arm Phase II trial that will assess the safety and efficacy of mitapivat, a pyruvate kinase-R (PKR) activator, in adult patients with erythrocyte membranopathies. Patients with membranopathy or congenital dyserythropoietic anemia type II (CDA II) will be enrolled in the trial. Dr Kuo outlines the eligibility criteria, planned study protocol, and primary and secondary outcomes of the study. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
